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28I ron is a vital element for numerous bodily functions, mostnotably as an ingredient of hemoglobin (Hb). Most healthypeople can achieve a stable iron balance, managing to
ingest the required amount of iron in the diet to compensate
for the small amount of daily iron losses from the gut.
However, many patients with advanced chronic kidney dis-
ease (CKD) are in negative iron balance as a result of reduced
dietary intake, impaired absorption from the gut, and
increased iron losses. This is particularly true in hemodialysis
(HD) patients, for whom supplemental iron is often essential
to keep pace with blood loss and the requirements for
erythropoiesis.
Intravenous iron is a highly effective means of replacing
iron deﬁcits and can enhance erythropoiesis, allowing lower
requirements for ESA therapy. This is particularly important
since the realization that ESA therapy may result in a
number of adverse clinical outcomes, most notably stroke,
venous thromboembolic disease, and vascular access
thrombosis. However, aside from changes in laboratory
parameters, the evidence base evaluating outcomes related to
the use of i.v. iron is sparse, and the effect of i.v. iron on hard
clinical outcomes including death and major health events
is uncertain. Moreover, there is evidence from laboratory,
animal, and observational studies that i.v. iron may exacer-
bate oxidative stress, potentiate atherogenesis and cardio-
vascular (CV) toxicity, and increase the propensity for
infections, as well as occasionally induce hypersensitivity
reactions.
This conference was convened to critically examine the
evidence base and to identify gaps in knowledge so as to
inform future clinical research. The four main themes dis-
cussed were: iron overload, oxidative stress, infections, and
hypersensitivity reactions.Kidney International (2016) 89, 28–39
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IRON OVERLOAD
Causes, deﬁnition, and diagnosis of iron deﬁciency
Patients with CKD are prone to iron deﬁciency, and its
etiology is multifactorial. The deﬁnition of iron deﬁciency can
be considered under 2 main categories: absolute, when there is
a deﬁciency of total body iron stores (Table 1); and functional,
when there are ample or increased total body iron stores, but
with sequestration of iron in the reticuloendothelial system
(RES), with inadequate iron supply for erythropoiesis.
With respect to functional iron deﬁciency, sequestration
of iron within the RES is primarily due to inﬂammation.
Since transferrin is a negative acute phase protein, serum
transferrin tends to be reduced in CKD patients.1 As a
result, total iron binding capacity is decreased. At a given
transferrin saturation, the absolute amount of iron bound to
transferrin in the circulation and available for erythropoiesis
is lower in CKD patients than in healthy people with
normal or near-normal kidney function. Stimulation of
erythropoiesis with ESAs creates an increased demand for
iron and can unmask and/or aggravate decreased iron
availability.
Iron loss is largely due to blood loss. The relation between
blood loss and iron loss depends on the Hb level (e.g., Hb
12 g/dl: 0.40 mg iron per ml blood; Hb 10 g/dl: 0.36 mg iron
per ml blood). In non-dialysis CKD patients, the average
gastrointestinal blood loss can be elevated (estimated blood
loss of 3.2 ml/d, approximately 1.2 L/yr, corresponding to
about 0.4 g iron/yr) as compared to that of healthy people
(0.83 ml/d, corresponding to about 0.1 g iron/yr).2 In HD
patients, some evidence indicates an even larger increase of
gastrointestinal blood loss (mean 5.0 ml/d).3 Procedure- and
laboratory test–related blood loss of patients on HD is of the
order of 2–5 l/yr,4 but may vary considerably over time and
among patients; blood loss is also inﬂuenced, for example, by
anticoagulant and antiplatelet agent prescription.5–7 In
aggregate, iron losses in HD patients are considered to be of
the order of 1–2 g/yr, but may be highly variable, and in some
patients may be as high as 4–5 g/yr.
Both ferritin and transferrin saturation have their short-
comings in assessing iron status and guiding iron therapy in
patients with CKD.8–11 The diagnosis of absolute ironTable 1 | Causes of absolute iron deﬁciency
 Blood loss for laboratory tests, aggravated by hospitalizations
 Gastrointestinal losses (may be exacerbated by systemic anti-
coagulation during dialysis, and/or the use of maintenance oral anti-
coagulants or antiplatelet drugs used for the treatment or prevention
of cardiovascular disease)
 Blood losses associated with the hemodialysis procedure, including
dialyzer blood loss and blood loss from the arteriovenous ﬁstula or graft
puncture site and from catheters
 Reduced intestinal iron absorption, at least in part due to increased
hepcidin levels, and medications (e.g., proton pump inhibitors and
calcium-containing phosphate binders)113–115
 Reduced intake due to poor appetite, malnutrition, and dietary advice
(e.g., protein restriction)
Kidney International (2016) 89, 28–39deﬁciency is usually based on low serum ferritin concentra-
tions (<20–30 mg/l) that reﬂect low body iron stores. In CKD
patients, because of the presence of inﬂammation, threshold
values indicating iron deﬁciency are generally considered to
be higher than in those without kidney disease. Serum ferritin
levels of 100 or 200 mg/l are frequently cited as a cutoff value
in non-dialysis CKD and dialysis patients, respectively.12
Although the evidence is rather limited, it is generally felt
that a transferrin saturation <20% is indicative of absolute
iron deﬁciency, although transferrin saturations above this do
not exclude this condition.12
Even when iron stores and circulating iron are sufﬁcient,
iron supply for erythropoiesis can be inadequate, as in in-
stances during intense stimulation of erythropoiesis with
ESAs, or under conditions of blocked iron release from
macrophages by inﬂammation.
Percentage of hypochromic red cells and reticulocyte Hb
content have been utilized as indicators of inadequate iron
supply,11,13 but problems of analyzer availability and the need
for the analysis to be performed soon after blood sampling
preclude their widespread adoption into routine clinical
practice.
Measuring serum hepcidin has been proposed as a means
of identifying patients who might beneﬁt from increasing
either ESA or i.v. iron dosing,14 but to date, such an approach
has not been shown to be clinically useful.13,15–17 Furthermore,
hepcidin assays are not harmonized or standardized.18–20
Doses of iron required to correct iron deﬁciency
Since the true amount of iron loss in individual patients and
patient groups is uncertain, the precise doses required to
compensate for this loss inevitably remain uncertain.
Applying doses of i.v. iron in excess of ongoing losses will
result in positive iron balance, the consequences of which are
unknown.
In general, i.v. iron doses in excess of 3 g/yr are likely to be
associated with an increased risk of exceeding the ongoing
iron loss and inducing positive iron balance. In patients who
routinely receive i.v. iron, higher requirements for i.v. iron to
maintain Hb within a target range, or within the patient’s
usual range, should prompt the search for increased losses,
particularly from the gastrointestinal tract.
Iron overload and its impact on organ function and patient
outcomes
There is no feasible method available to determine total body
iron content. Thus, the present deﬁnitions of iron deﬁciency
and overload remain imperfect, and one has to rely on pre-
sumed functional consequences of decreased or increased
iron stores and surrogate markers.
Iron overload represents a condition of increased total
body iron content that is possibly associated with a time-
dependent risk of organ dysfunction. Pathologic iron over-
load represents a condition of increased body iron content
associated with signs of organ dysfunction that are presum-
ably caused by excess iron.29
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on a variety of factors, including the distribution of iron
among parenchymal cells and cells of the RES, the duration of
iron excess in relation to the life expectancy of the patient,
comorbidities, and others. The circumstances under which
increased iron content is associated with clinically relevant
adverse consequences and the nature of these consequences
are insufﬁciently deﬁned. Observations in patients with
inherited hemochromatosis suggest that parenchymal iron
excess and labile iron can be harmful, whereas iron stored
within cells of the RES may be of less concern,21,22 although
intrahepatic iron might induce hepatic damage through iron-
induced mesenchymal activation.23
Serum ferritin, when elevated, does not always correlate
with elevations in liver iron content.24–26 Hyperferritinemia is
thus not synonymous with iron overload, and the level of
serum ferritin does not indicate whether iron is stored in
parenchymal cells or cells of the RES.27 Since high transferrin
saturation facilitates parenchymal iron deposition, of partic-
ular concern appears to be a combination of high transferrin
saturation and high serum ferritin, based on experience in
patients with hereditary hemochromatosis28 and transfusion-
induced iron overload.29
Magnetic resonance imaging scans have been shown to
provide a reliable estimate of tissue iron content in non-CKD
populations,30,31 and measurements in unselected HD pa-
tients suggest that liver iron content is increased compared to
reference values in the majority of patients.32 However, the
clinical relevance of increased liver iron content in the
absence of elevated liver enzymes is unclear. At present, there
is insufﬁcient evidence to support the use of hepatic magnetic
resonance imaging in guiding iron therapy in clinical practice.
Organ toxicity associated with iron overload in hemato-
logic diseases depends on various factors, including the
magnitude and speed of iron accumulation. The main target
organs are liver, myocardium, endocrine glands, and
joints.28,33 However, the magnitude, distribution, and dura-
tion of iron accumulation in CKD patients may be insufﬁcient
to produce toxicity similar to that observed in hemochro-
matosis. Given that i.v. iron use has increased markedly in
HD patients over the past few years,34,35 the exposure to
higher amounts may not have accrued long enough to detect
such toxicity. Although end-organ damage from i.v. iron
administration in patients with kidney disease has not been
unequivocally established, at present one cannot exclude the
toxicity potential of iron induced by repeated high-dose i.v.
iron administration in CKD.
OXIDATIVE STRESS IN UREMIA
Oxidative stress or oxidant-derived tissue injury results from
an overproduction of reactive oxygen/nitrogen species or
impairment in the cellular antioxidant enzymatic activities,
leading to oxidation of macromolecules such as proteins,
carbohydrates, lipids, and DNA. Increased levels of oxidative
stress markers are present in uremic plasma and are thought
to be ﬁngerprints of increased oxidative stress (Figure 1).30Oxidative stress occurs early in the evolution of impaired
kidney function and is believed to herald a poor prognosis,36
and often associates with persistent inﬂammation.37 Although
numerous markers are now available for estimating oxidative
stress,37 practical concerns, such as absence of established
reference ranges, variable analytical techniques, and the lack
of understanding regarding the relations between markers
and impaired kidney function and associated comorbidities,38
preclude their widespread adoption in the clinical setting.
Thus, at the present time there is no gold standard for
measuring or monitoring oxidative stress to guide clinical risk
assessment or prognosis.
Clinical studies in CKD patients have shown that i.v. iron
administration promotes oxidative damage to peripheral
blood lymphocyte DNA,39 protein oxidation,40 and lipid
peroxidation.41 In addition to direct pro-oxidative effects,
studies have shown that administration of i.v. iron com-
pounds promotes cellular apoptosis,42 endothelial dysfunc-
tion,43,44 and monocyte adhesion.42,43
Iron-mediated oxidative stress and CV risk
Despite numerous basic and clinical studies, the question of
whether or not iron administration promotes atherosclerosis
and arterial remodeling remains unresolved. Moreover,
although iron has been detected in human atherosclerotic
plaques,45 it is not yet proven that this accumulation is
deleterious and promotes CV disease. A recent study in ApoE
knockout mice and ApoE/ffe mice fed with a high-fat diet
demonstrated that the atherosclerotic plaque size was not
increased in mice with elevated macrophage iron.46 In
contrast, a recent study in the mouse remnant kidney model
showed that iron sucrose aggravated early atherosclerosis by
increasing monocyte-endothelial adhesion and increased su-
peroxide production.47 In a cohort of 58,058 HD patients, i.v.
iron doses greater than 400 mg/mo were associated with
higher CV death rates.48 Although clinical studies have also
demonstrated signiﬁcant correlations among cumulative iron
dose, intimal media thickness,49,50 and CV events,51 these
ﬁndings are difﬁcult to interpret because of their observa-
tional nature and confounding by indication. A recent
retrospective study of 117,050 HD patients showed no asso-
ciation between large doses of iron and short-term CV
morbidity and mortality.52
Increased hepcidin: important mediator of CV risk?
Hepcidin is the key iron regulatory protein synthesized in the
liver that is sensitive not only to iron deﬁciency but is also
upregulated in response to increased circulating and stored
iron levels,53 inﬂammation,54 and infections,55 and is down-
regulated by hepcidin inhibitors, including testosterone,56
estrogen,57 and erythroferrone.58 Some studies suggest that
increased hepcidin may increase CV risk by preventing
mobilization of iron from macrophages (Figure 2). Hepcidin
and macrophage iron correlate with monocyte chemo-
attractant protein-1 release and vascular damage in patients
with metabolic disease.59 Moreover, in a clinical study of 766Kidney International (2016) 89, 28–39
Figure 1 | Schematic representation of oxidation and antioxidant pathways in chronic kidney disease. AGEs, advanced glycation end
products; CytP450, cytochrome P450; GSH, reduced glutathione; GSH-Px, glutathione peroxidase; GSSG, oxidized glutathione; MPO, myelo-
peroxidase; NADPH, nicotinamide adenine dinucleotide phosphate; NOS, nitric oxide synthase; ONOO-, peroxynitrite; SOD, superoxide dis-
mutase. Reproduced with permission from Stenvinkel et al.110
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ated with the presence of atherosclerotic plaques.60 Indirect
evidence for a proatherogenic role of hepcidin comes from a
study that shows that pharmacological suppression ofFigure 2 | Proposed mechanisms underlying the hepcidin-induced p
suppresses iron release from macrophages via downregulation of iron-ex
in accumulated intracellular lipids and enhanced oxidative stress, inﬂam
essential for Ox-LDL–mediated phenotypic switching of iron-loaded ma
ferroportin 1; IL-6, interleukin-6; MCP-1, monocyte chemoattractant prote
lipoprotein; SMCs, smooth muscle cells; TNF-a, tumor necrosis factor-a.
Kidney International (2016) 89, 28–39hepcidin increases macrophage reverse cholesterol transport
and limits atherosclerosis.61 In the context of CKD, the evi-
dence that links increased hepcidin to CV disease is limited.
However, one study showed an association between increasedlaque instability. In the setting of erythrophagocytosis, hepcidin
porting protein Fpn1 and increases iron storage. Iron trapping results
matory responses, and macrophage apoptosis. Thus, hepcidin is
crophages leading to atherosclerotic plaque destabilization. Fpn1,
in-1; MMP-2, matrix metalloproteinase-2; Ox-LDL, oxidized low-density
Caption text and ﬁgure reproduced with permission from Li et al.111
31
meet ing repor t IC Macdougall et al.: Iron management in CKD: a KDIGO executive summary reporthepcidin and arterial stiffness,62 and in the Convective
Transport Study (CONTRAST) of 405 HD patients, serum
hepcidin-25 was related to CVevents even after correction for
the presence of inﬂammation.63
Increased ferritin: a surrogate marker or a real risk factor?
Increased circulating concentrations of ferritin are frequently
observed in patients with CKD.32,64 However, like hepcidin,
ferritin is also signiﬁcantly upregulated in the acute phase
response and particularly in the presence of low serum iron,
transferrin, and transferrin saturation, and is just as likely to
reﬂect an inﬂammatory as an iron-replete state. In the general
population, high serum ferritin is associated with an
increased risk of myocardial infarction65 and carotid pla-
ques.66 In patients with CKD, the associations between iron
parameters and outcomes are confounded by multiple factors.
One study reported that low serum iron is a predictor of poor
outcome67 even after adjustment for ferritin and the in-
ﬂammatory marker C-reactive protein. In contrast, another
observational study of 58,058 HD patients showed an asso-
ciation between high ferritin (>800 ng/ml) and mortality,
which was markedly attenuated following the correction for
markers of malnutrition and inﬂammation.48 Since correc-
tion for markers of inﬂammation markedly attenuated the
risk associated with hyperferritinemia, prospective controlled
studies are needed to assess whether hyperferritinemia-
associated CV risk merely represents a risk marker or is in
fact a risk factor.
Can antioxidants blunt potential pro-oxidative effects of iron
supplementation?
Although some studies have shown beneﬁcial effects of a
single dose of vitamin E68 or short treatment with N-ace-
tylcysteine69 on surrogate markers of lipid peroxidation, it
would be premature to recommend a single antioxidative
therapy prior to iron supplementation. Indeed, a study in 13
HD patients showed that the combination of i.v. iron and
vitamin C was actually associated with an increased produc-
tion of reactive oxygen species.70 It can be speculated that in
the presence of poorly liganded iron, molecules that are
normally antioxidants can actually act as pro-oxidants by
reducing ferric iron to catalytically active ferrous iron. A
recent randomized controlled trial (RCT) in 353 HD patients
examining the effects of 6 months of antioxidative therapy
(tocopherols and a-lipoic acid) failed to inﬂuence biomarkers
of inﬂammation and oxidative stress.71 Thus, we currently do
not know whether increased oxidative stress in the uremic
milieu responds to antioxidative treatment strategies.
IRON ADMINISTRATION AND RISK OF INFECTIONS
Iron is of central importance in host-pathogen interaction
because of its key role in biological processes including
mitochondrial respiration and DNA synthesis.72,73 Accord-
ingly, the proliferation and pathogenicity of many micro-
organisms, such as bacteria, viruses, parasites, helminths,
and fungi, are dependent on the availability of iron.74,75 Iron32also exerts subtle effects on host immune function by
modulating immune cell proliferation and differentiation
and by directly regulating cytokine formation and antimi-
crobial immune effector mechanisms. Thus, imbalances of
iron homeostasis can affect the risk for, and the outcome of,
infections.74,76,77
Clinical epidemiologic evidence
Data from patients on HD. Ishida and Johansen78 critically
reviewed the association between iron and infection in pa-
tients receiving HD. These authors identiﬁed studies that
evaluated the association between serum ferritin (13 studies)
and iron usage (24 studies) and the risk of infection.
Among the 13 studies that examined the risk of infection
according to serum ferritin, 9 reported an association and 4
did not. Studies showing associations generally reported a 1.5-
to 3.1-fold higher incidence of bacterial infection or
infection-related mortality, which translates into an excess of
16–50 bacterial infections per 100 patient-years among pa-
tients with higher serum ferritin.
Among the 24 studies that evaluated iron usage and
infection, the results were equivocal, as 12 observational
studies reported an association while 10 did not. Two RCTs
also did not uncover an association though they were not
primarily designed to assess the risk of infection.79–81 Among
the 12 studies showing an association between iron usage and
infection, data from the United States Renal Data System
reported a 14%–45% higher risk of infection-related mor-
tality with higher frequency and higher dose of i.v. iron,78 and
Dialysis Clinics Inc. found that higher mean i.v. iron dose per
dialysis treatment was independently associated with a higher
risk of infection-related mortality at 6 months compared to a
lower mean i.v. iron dose or no iron.78
Only 2 studies have examined the risk of infection with
different i.v. iron formulations. In one study of 63 HD pa-
tients, the adjusted relative risks for bacteremic episodes with
iron sucrose versus ferric gluconate were 2.92 (95% conﬁ-
dence interval 1.01–8.50) and 2.84 (95% conﬁdence interval
1.32–6.09), respectively.82 In another study of 559 patients,
mean i.v. iron sucrose dose was signiﬁcantly higher in patients
with catheter-related sepsis than in patients without; similar
ﬁndings were reported in patients who received i.v. iron
dextran.83
In one study of 117,050 patients comparing mortality with
different dosing patterns of i.v. iron,84 the authors reported
that bolus dosing, when compared to maintenance dosing,
was associated with a higher risk of infection-related hospi-
talization, the risk being highest among patients with a
catheter or history of recent infection. An association between
bolus dosing and infection-related mortality was also
observed. In contrast, maintenance or low-dose iron dosing
was not associated with a higher risk of infection-related
hospitalization or mortality outcomes when compared with
no iron.
More recent data. A multicenter study from Japan pro-
spectively evaluated the association between serum ferritinKidney International (2016) 89, 28–39
Table 2 | General classiﬁcations of drug hypersensitivity
reactions
Anaphylactic reactions
 Characterized by 2 or more organ systems involved (skin, gut, respira-
tory, cardiovascular)
 Objective evidence of bronchoconstriction, stridor, hypotension, severe
generalized urticaria, nausea, abdominal pain
Minor infusion reaction
 Often described as pressure in the chest or lumbar region, associated
with ﬂushing, with or without minor urticaria, but no hypotension or
other organ involvement
Flare in pre-existing immune and/or inﬂammatory conditions,
particularly rheumatoid arthritis
 Manifesting as arthralgia
It is generally not possible to predict those at risk for a hypersensitivity
reaction, but the following patient characteristics may indicate a higher
risk:
 Prior reaction to any i.v. iron formulation
 Moderate to severe asthma
 Multiple pre-existing drug hypersensitivities or allergies116
 Pre-existing immune-mediated disease (e.g., autoimmune disorders)
 Mast cell–associated disorders
 High transferrin saturation or low plasma transferrin levels, which may
increase the likelihood of circulating labile iron during infusion117,118
Local skin reactions to extravasated iron can occur. Infusion-speciﬁc risk
factors such as use of higher doses and rapid rate of infusion118 should
also be considered when evaluating for any potential reactions. Whether
generic formulations have a greater propensity for increased labile iron
reactions is as yet unclear.
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among 1086 HD patients. The authors reported a signiﬁcantly
higher risk of infection with higher serum ferritin compared
to lower ferritin, and with high and even low doses of i.v. iron
compared with no i.v. iron.85 In contrast to the Japanese
study, the outcomes of 32,435 patients receiving i.v. iron in
12 countries were analyzed,86 and, when compared to patients
receiving 100–199 mg/mo, those receiving an average of
300–399 mg/mo or $400 mg/mo had a higher risk of
all-cause mortality, but no signiﬁcant increase in mortality
due to infection. In another incident cohort of 9544 US
dialysis patients, a higher cumulative dose of i.v. iron was not
associated with infection-related hospitalizations,87 while
another prospective, observational study of 235 incident
dialysis patients reported that those who received i.v. iron had
a signiﬁcantly lower all-cause mortality, including marginally
lower sepsis-related mortality.88
Lastly, a meta-analysis that evaluated the safety and efﬁcacy
of i.v. iron therapy for functional iron deﬁciency reported no
association of i.v. iron with risk of infection, but only limited
conclusions could be drawn as it only included 2 studies
comprising 359 analyzable patients.89 In contrast, a recent
systematic review and meta-analysis of RCTs evaluating the
safety and efﬁcacy of i.v. iron therapy, which included HD
and non-dialysis CKD patients, reported that i.v. iron was
associated with a signiﬁcantly higher risk of infection
compared with either oral iron or no iron supplementation.90
However, these ﬁndings were tempered by the fact that
infection was not a predeﬁned end point in many of the
pooled studies and thus the introduction of unmeasured bias
cannot be excluded.91
Data from peritoneal dialysis and nondialysis CKD patients.
Scant data are available regarding the effect of i.v. iron therapy
and the risk of infection in peritoneal dialysis or non-dialysis
CKD patients. In a study of 379 peritoneal dialysis patients,
there were more peritonitis episodes during the 6 months
after i.v. iron infusion, especially with iron dextran, compared
to the peritonitis episodes during the 6 months before iron
infusions (15 episodes vs. 8 episodes, respectively, in 6
months), but the difference was not statistically signiﬁcant.92
A recent RCT by Agarwal et al.93 comparing oral versus i.v.
iron in non-dialysis CKD patients showed a higher rate of
serious adverse events in the i.v. iron treatment group, with
increased CV events and infections requiring hospital
admission. However, this study examined a single center, with
a single investigator adjudicating all serious adverse events
and only 99 subjects completing the trial. It is also of concern
why the ﬁndings of Agarwal et al.93 are so discrepant
with those reported in the much larger FIND-CKD study,94
a multicenter study conducted in 626 non-dialysis CKD pa-
tients worldwide and with considerably greater patient-years
of follow-up. Even though patients were treated with much
higher doses of i.v. ferric carboxymaltose (FCM) in FIND-
CKD, no safety signals were evident, and indeed the in-
cidences of infections (adverse events: 33.1% vs. 34.0% vs.
30.4%; serious adverse events: 3.9% vs. 3.3% vs. 3.8%) andKidney International (2016) 89, 28–39cardiac events (6.5% vs. 4.7% vs. 4.5%) were identical across
all 3 groups (high-ferritin FCM, low-ferritin FCM, and oral
iron, respectively).
In summary, the evidence base for iron administration
and risk of infection derives mostly from observational
studies conducted in HD patients, which are prone to
confounding. The few RCTs conducted in this area included
a small number of patients with a short follow-up and were
not speciﬁcally designed to assess the risk of infection
with i.v. iron, while several systematic reviews and meta-
analyses performed to date are inconclusive. Despite the
conﬂicting evidence concerning i.v. iron use and the risk of
infections, we concluded that the current KDIGO recom-
mendations, which call for balancing potential beneﬁts
versus risks of i.v. iron therapy, as well as advising against
i.v. iron use in patients with an active systemic infection,
are still prudent.HYPERSENSITIVITY
The safety of administration of i.v. iron compounds has been
of concern given the well-recognized risk of life-threatening
adverse reactions to high–molecular weight iron dextran
and other older formulations. Although it is accepted that the
dextran component of the formulation is likely to be the
cause of these reactions, the general risk of parenteral iron
administration needs to be clariﬁed now that newer formu-
lations are available that allow complete replacement doses in
15–60 minutes, and novel methods of iron delivery such as
iron supplementation in the dialysate and iron-containing33
Adverse drug reaction to i.v. iron therapy
Nonspecific symptoms
Chest tightness, dizziness, 
lightheadedness, nausea, 
itching, asymptomatic 
hypotension
Mild infusion reaction
Nonspecific symptoms 
PLUS urticaria
Severe chest pain
Cough
Nausea
Tachycardia
Hypotension
Severe reaction
Sudden onset of:
Wheezing, stridor, cyanosis, 
hypotension, tachycardia
STOP infusion
Observe 15 minutes
Restart if well at 25%–50% 
rate; if recurs, stop 
STOP infusion
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Retrial after steroid 
or oral H1 blocker 
(1 hr after treatment)
STOP infusion 
Give i.v. fluids
i.v. steroid 100 mg 
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H1 blocker
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15 L Oxygen
0.5 mg 1:1000 IMI
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agonist 
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ADMIT
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risk
Figure 3 | Suggested management of reactions to i.v. iron. Optimal clinical treatment of severe anaphylaxis includes adrenaline as an
essential anti-anaphylactic drug given by intramuscular injection of 0.5 mg in 1:1000 solution. This should be repeated after 5–10 minutes
if needed. Additional supportive oxygen should be given at a high rate (>15 liters/min) by face mask. Volume loading should be given using
1 liter of crystalloid solution in addition to an antihistamine (H1 blocker) and corticosteroids to prevent a protracted or biphasic course of
anaphylaxis.112 For nonspeciﬁc reactions, stopping the infusion for at least 15 minutes and monitoring the response (i.e., pulse, blood pressure,
respiratory rate, and oxygen saturation) may be sufﬁcient. If the patient improves, then the iron infusion can be resumed at 25%–50% of the
initial infusion rate with monitoring. For mild reactions, if treatment is restarted, i.v. H1 blockers and corticosteroids should be considered and
monitoring after therapy should be continued for 1 hour. If the infusion is discontinued and the reaction subsides, then rechallenge with the
same or a different iron preparation may be undertaken in an environment where monitoring is available. A much lower dose of the iron
preparation or slower infusion rate should be considered to gain reassurance that this reaction is likely to be dose-related and possibly due
to labile iron release. IMI, intramuscular injection; IVI, intravenous infusion.
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these reactions, the conference attendees deemed it a high
priority to assess the characteristics of reactions to i.v. iron as
well as to provide advice on how these reactions should be
managed.
Reactions to i.v. iron
Side effects of oral iron are common, occurring in up to 60%
of patients,95 and these predominantly include constipation
and nausea, which could result in reduced adherence to oral
iron intake. Anaphylaxis to oral iron supplementation has
been reported but is extremely rare.9634Intravenous iron was initially administered as iron oxide
and was found to have an unacceptably high rate of toxic
reactions.97 Toxicity was largely thought to be attributable to
labile iron, and subsequent iron preparations have been
formulated with the iron salt encased in a carbohydrate
shell, commonly a dextran polymer, sucrose, or gluconate.
The resultant size of the complex determines the degradation
kinetics, with iron dextran releasing iron more slowly than
the lower–molecular weight formulations. Hence, lower doses
of iron sucrose and iron gluconate are recommended when
given as a single infusion to minimize the risk of higher levels
of labile iron and of potential reactions. With the exception ofKidney International (2016) 89, 28–39
Table 3 | Practical tips for management of hypersensitivity reactions to i.v. iron
 The ﬁrst dose (either in a CKD or dialysis setting) should be administered in a clinical facility.
 Although total-dose iron infusions have not been demonstrated to have signiﬁcant risk,119 i.v. doses of iron gluconate or iron sucrose should not
exceed 125 or 200 mg/dialysis, respectively, because of the potential risk for iron not binding immediately to transferrin and resulting in a
reaction due to labile iron.
 There is no physiological basis to recommend that patients should be observed for 30 minutes after an infusion of iron is completed, since i.v. iron
delivery should not be associated with a severe delayed reaction (as is observed with subcutaneous antigen presentation in vaccination or allergen
immune therapy).
 There is no evidence that pretreatment with corticosteroids or antihistamines (H1 channel blockers) reduces the risk of severe reactions to i.v. iron.
Paradoxically, i.v. antihistamines may be associated with unwanted side effects, particularly drowsiness or ﬂushing upon rapid infusion.120 Hence no
pretreatment with corticosteroids or antihistamines is recommended in patients identiﬁed as being at potential risk of a hypersensitivity reaction.
Desensitization protocols to limit hypersensitivity reactions are not established and, therefore, not recommended.
 Jurisdictional requirements regarding the use of i.v. iron vary and thus, should be followed closely. For example, in 2013 the EMA made recom-
mendations following reports of several hypersensitivity reactions in 3 pregnant women receiving low–molecular weight iron dextran compounds,121
all of whom made a complete recovery. The recommendations were extrapolated to all patient groups receiving any i.v. iron compounds. This
conference agreed with the current position of the EMA that all i.v. iron preparations can rarely cause hypersensitivity reactions, though the total number
of life-threatening reports is low. Although the data show a clear association of iron medications and hypersensitivity reactions, the data cannot be used
to detect differences in the safety proﬁles of different formulations. The attendees concurred that i.v. iron should not be administered in the ﬁrst trimester
of pregnancy. It was also agreed that a test dose was not useful in any circumstance to predict the risk of hypersensitivity to i.v. iron.
CKD, chronic kidney disease; EMA, European Medicines Agency.
Table 4 | Research recommendations
 The roles of low-protein diets and the effects of concomitant drugs on iron deﬁciency are still poorly understood. A better understanding of the
mechanisms and determinants of oral iron absorption will facilitate identiﬁcation of predictors of iron absorption that could stratify patients for
future trials with oral iron.
 Estimates of iron loss are generally limited to procedure-related and lab test–related losses only, but not GI loss. More precise estimates of iron loss in
the gut should be performed in larger and unselected HD and non-HD patient and CKD populations.
 The development of a methodology to objectively determine body iron stores and tissue distribution in CKD and ESRD patients would be highly
valuable. The role of MRI in detecting clinically relevant changes in tissue iron content (i.e., iron uptake in the Kupffer cells of the RES vs. in hepatocytes
of the liver parenchyma) should be further ascertained. Can iron accumulation potentially aggravate other comorbidities in CKD patients (e.g., viral
hepatitis, non-alcoholic steatohepatitis)?
 Studies should evaluate whether thresholds for increased risk of organ damage in patients with HFE hereditary hemochromatosis (i.e., TSAT >45%,
ferritin >1000 mg/l) are applicable to patients with CKD and whether less strikingly abnormal values are also markers for harm.
 Studies should be conducted to determine whether treatment with iron has clinically relevant beneﬁcial effects beyond stimulation of erythropoiesis
in patients with CKD. This concept has been reported in patients with CHF,122 as well as in patients with pulmonary arterial hypertension,123 restless
leg syndrome,124,125 and premenopausal women with low ferritin levels.126,127
 The role of hepcidin as a predictor for progression of anemia and CV events in CKD nondialysis patients should be further clariﬁed.34,35,128 Further
research should also clarify whether hepcidin has independent proatherogenic effects in the uremic milieu and whether its modulation may
mitigate arterial remodeling and atherosclerosis.
 Studies are needed to determine whether decreased antioxidative defense mechanisms in the uremic milieu may prolong and/or increase the
magnitude of oxidative stress following iron injections.129 Since the available i.v. iron formulations are structurally heterogeneous with different
stability and pharmacokinetic proﬁles,130 further research should be conducted to dissect the speciﬁc effects of various i.v. iron compounds on the
magnitude and time response of both established and novel oxidative stress biomarkers.
 Prospective controlled studies are needed to examine whether iron promotes atherosclerosis and arterial remodeling and accelerates CV mortality,
especially in vulnerable subgroups such as CKD patients with diabetes mellitus and/or persistent inﬂammation.
 There is an urgent need for RCTs to assess the relative safety and efﬁcacy of i.v. iron in the management of CKD-related anemia, particularly in relation
to hard clinical end points, as well as infection risk and other patient-related outcomes. Improved methodologic aspects of RCT design to consider
include (i) random allocation of patients to high-dose vs. low-dose i.v. iron, high vs. low serum ferritin target, bolus vs. maintenance dosing, and
different i.v. iron formulations vs. placebo; (ii) use of cluster RCTs (i.e., randomized to facility practice); (iii) use of rescue therapy for patients who
develop iron deﬁciency to maintain the Hb level above 9 g/dl (10–12 g/dl); (iv) use of a ﬁxed dose of ESA; (v) inclusion of outcomes such as ESA dose,
blood transfusions, infection, mortality, CV events (e.g., stroke and myocardial infarction), quality of life, and other patient-related outcomes.
 Observational studies should be conducted in predialysis CKD patients, kidney transplant recipients, and peritoneal dialysis patients to determine
infection and CV risks, and possible beneﬁts with i.v. iron in these populations.
 Experimental studies using uremic animal models should be performed to test the effects of i.v. iron on active infection and the risk of developing
new-onset infections with pathogens most commonly encountered in the CKD population (e.g., Staphylococcus aureus, coagulase-negative
Staphylococcus, and gram-negative bacteria). Do iron perturbations result in exacerbation of latent or chronic infections such as tuberculosis, subacute
bacterial endocarditis, or hepatitis C?
 A standardized questionnaire should be used to report any adverse reaction from an i.v. iron preparation using an adapted version of Ring and
Messmer’s classiﬁcation of adverse drug reactions.131 If implemented, this questionnaire could be used across jurisdictions and help identify patients
at risk for i.v. iron preparations that carry a higher risk of adverse drug reactions.
 Future research should ideally address the value of tryptase measurements in acute hypersensitivity reactions. Importantly, measurements should not
be taken immediately after a reaction, but at least 1 hour after the onset of symptoms and supplemented by a baseline tryptase measurement a few
days later. Additional measurement of complement factors C3a/C5a and C4 could provide information on the presence of immune-mediated
reactions.
CHF, congestive heart failure; CKD, chronic kidney disease; CV, cardiovascular; ESA, erythropoiesis-stimulating agent; ESRD, end-stage renal disease; GI, gastrointestinal;
Hb, hemoglobin; HD, hemodialysis; MRI, magnetic resonance imaging; RCT, randomized controlled trial; RES, reticuloendothelial system; TSAT, transferrin saturation.
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ences in adverse reactions among different formulations
cannot be quantiﬁed and are unlikely to be signiﬁcant given
the low incidence of reactions. However, a strong consensus is
that higher–molecular weight iron dextran should not be
used, given that alternative formulations are now available
with lower absolute risks of reactions.
In non-dialysis CKD and dialysis patients, with or without
concomitant ESA use, the advent of formulations available for
more rapid infusion (e.g., lower–molecular weight iron
dextran, FCM, iron isomaltoside 1000, and ferumoxytol)
could provide considerable beneﬁt. These formulations may
be viable alternatives to oral iron supplementation and,
despite their higher drug acquisition costs, may be cost-
effective in certain health-care settings.98–101
Given the lack of clarity on the cause of systemic reactions
to i.v. iron, we suggest a classiﬁcation according to the severity
of reaction, which can then be used to recommend the sub-
sequent approach to both acute and longer-term therapy
(Table 2).
Anaphylactic (severe to life-threatening) reactions. It has
been shown that higher–molecular weight iron dextran had
3–4 times the rate of life-threatening adverse reactions at
11.3 per million patients compared with 3.3 per million
patients for lower–molecular weight iron dextran, and
0.9 and 0.6 per million population for ferric gluconate and
iron sucrose, respectively.102 Excluding higher–molecular
weight iron dextran, which is no longer commercially avail-
able, anaphylactic reactions are extremely rare, with an inci-
dence of <1:200,000. The US Food and Drug Administration
recently posted a regulatory update regarding severe hyper-
sensitivity reactions with ferumoxytol, along with advice to
slow down the rate of administration.103
To date, pharmaceutical ﬁling and published trials have not
demonstrated anaphylactic reactions with intradialytic
administration of soluble ferric pyrophosphate104 or oral
ferric citrate105 or with another iron compound currently
under development, heme iron polypeptide.106 However,
given the rarity of reactions with any form of iron adminis-
tration, it cannot be concluded that oral or intradialytic
administration of iron is without risk.
So far there is no established and validated allergological
work-up such as skin testing or in vitro tests available
to predict or conﬁrm hypersensitivity. Improved clinical
documentation of hypersensitivity reactions to iron in the
future should also include an allergological work-up to
identify possible, but as-yet unproven, risk factors such as
asthma, mastocytosis, concurrent use of drugs (e.g., beta
blockers and angiotensin-converting enzyme inhibitors), and
atopic status.
Minor infusion reactions. Minor infusion reactions are not
uncommon and may be characterized by symptoms such as
ﬂushing, mild chest discomfort, dizziness, light-headedness,
nausea, or itching. In practice, asymptomatic hypotension is
sometimes observed, but this is considered a nonspeciﬁc re-
action unless iron is a known allergen for the patient from36prior administration. Some patients may develop myalgia or
arthralgia (the so-called Fishbane reaction), which is usually
self-limiting and does not require treatment with adrenaline
or antihistamines. These mild infusion reactions may be
diagnosed via their ability to resolve when the infusion is
stopped or given at a slower rate107 and should generally not
preclude the ongoing use of i.v. iron preparations.
Management of hypersensitivity reactions to i.v. iron.
Patients who have had a life-threatening reaction to i.v. iron
should not receive further i.v. iron compounds. However, if
patients experienced more minor features of hypersensitivity,
then an alternative formulation could be tried at a later date
with appropriate monitoring.108 A consensus algorithm for
the management of reactions to i.v. iron is shown in Figure 3.
Practical management tips are also provided in Table 3.
CONCLUSION
Present available data do not allow any ﬁrm statement to be
made on the potential dangers of high-dose iron adminis-
tration and high ferritin levels. However, this conference has
identiﬁed gaps in knowledge to inform future research
agendas (Table 4) and concluded that RCTs are urgently
required to address the shortfall in the evidence base. An
ongoing trial, PIVOTAL,109 is recruiting 2080 HD patients
across 55 sites in the UKwho are being randomized to a high-
dose versus a low-dose i.v. iron regimen with a planned
follow-up of between 2 and 4 years. Hard end points such as
death, myocardial infarction, stroke, heart failure, and in-
fections are being assessed. In the meantime, nephrologists
would do well to recognize broadly the beneﬁts and the
limitations of i.v. iron therapy, pending further robust sci-
entiﬁc data.
DISCLOSURE
ICM declared having received consultancy fees from AMAG,
Pharmacosmos, Takeda and Vifor; speaker honoraria from Vifor; and
research support from Vifor Fresenius Medical Care Renal Pharma.
AJB declared having received speaker honoraria from Vifor. K-UE
declared having received consultancy fees from Amgen, Johnson &
Johnson, Sandoz-Hexal, and Vifor and speaker honoraria from Amgen
and Roche. GTO declared having received consultancy fees from
Abbvie and Amgen and speaker honoraria from Abbott Nutrition,
Abbvie, and Amgen. CAP declared having received consultancy fees
from Amgen Australia, Astra Zeneca, Boehringer Ingelheim, Janssen
Cilag, and Merck Sharp & Dohme; speaker honoraria from Astra
Zeneca, Janssen Cilag, and Merck Sharpe & Dohme; and research
support from Australian Research Council, Diabetes Australia, Hillcrest
Foundation and JDRF. PS declared having received consultancy fees
from Abbvie, Amgen, Keryx, Pﬁzer, and Vifor and speaker honoraria
from Asahi, Bayer, and Keryx. DWS declared having received research
support from EUROCALIN (EUROpean Consortium for AntiCALINS)
and applied for research funding from the Dutch Kidney Foundation.
As an employee of Radboud University Medical Center, DWS is also
afﬁliated with its Hepcidinanalysis.com initiative, which offers
hepcidin measurements to the scientiﬁc, commercial, and clinical
community on a fee-for-service basis. CW declared having received
consultancy fees from Boehringer Ingelheim and Genzyme; speaker
honoraria from Abbvie, Amgen, Boehringer Ingelheim, CorMedix,
Genzyme, Merck Sharp & Dohme, Pﬁzer, and Sanoﬁ; and research
support from Genzyme. GW declared having received speakerKidney International (2016) 89, 28–39
IC Macdougall et al.: Iron management in CKD: a KDIGO executive summary report mee t ing repor thonoraria from Pharmacosmos and Vifor. GMC declared having
received consultancy fees from AMAG and research support from
Amgen (personally received 1% from grant support). The conference
was sponsored by KDIGO and supported in part by unrestricted
educational grants from Akebia Therapeutics, Amgen, Bayer
HealthCare, F. Hoffmann-La Roche Ltd., FibroGen, Keryx
Biopharmaceuticals, Rockwell Medical, Pharmacosmos, and Vifor
Fresenius Medical Care.SUPPLEMENTARY MATERIAL
Complete Conference Report
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
REFERENCES
1. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in
hemodialysis patients. Am J Kidney Dis. 1999;34:21–28.
2. Rosenblatt SG, Drake S, Fadem S, et al. Gastrointestinal blood loss
in patients with chronic renal failure. Am J Kidney Dis. 1982;1:
232–236.
3. Wizemann V, Buddensiek P, de Boor J, et al. Gastrointestinal blood loss
in patients undergoing maintenance dialysis. Kidney Int Suppl. 1983;16:
S218–S220.
4. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood
Purif. 2004;22:112–123.
5. Flint S, Taylor E, Beavis J, et al. Increased iron requirement in
hemodialysis patients on antiplatelet agents or warfarin. Nephron Clin
Pract. 2009;113:c38–c45.
6. Holden RM, Harman GJ, Wang M, et al. Major bleeding in hemodialysis
patients. Clin J Am Soc Nephrol. 2008;3:105–110.
7. Landefeld CS, Goldman L. Major bleeding in outpatients treated with
warfarin: incidence and prediction by factors known at the start of
outpatient therapy. Am J Med. 1989;87:144–152.
8. Fishbane S, Kowalski EA, Imbriano LJ, et al. The evaluation of iron status
in hemodialysis patients. J Am Soc Nephrol. 1996;7:2654–2657.
9. Kalantar-Zadeh K, Hoffken B, Wunsch H, et al. Diagnosis of iron deﬁciency
anemia in renal failure patients during the post-erythropoietin era. Am J
Kidney Dis. 1995;26:292–299.
10. Stancu S, Barsan L, Stanciu A, et al. Can the response to iron therapy be
predicted in anemic nondialysis patients with chronic kidney disease?
Clin J Am Soc Nephrol. 2010;5:409–416.
11. Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers
in predicting response to intravenous iron in haemodialysis patients
on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16:
1416–1423.
12. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work
Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney
Disease. Kidney Int Suppl. 2012;2:279–335.
13. Tessitore N, Girelli D, Campostrini N, et al. Hepcidin is not useful as a
biomarker for iron needs in haemodialysis patients on maintenance
erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2010;25:
3996–4002.
14. Swinkels DW, Wetzels JF. Hepcidin: a new tool in the management of
anaemia in patients with chronic kidney disease? Nephrol Dial Transplant.
2008;23:2450–2453.
15. Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are
elevated but responsive to erythropoietin therapy in renal disease.
Kidney Int. 2009;75:976–981.
16. van der Putten K, Jie KE, van den Broek D, et al. Hepcidin-25 is a marker
of the response rather than resistance to exogenous erythropoietin in
chronic kidney disease/chronic heart failure patients. Eur J Heart Fail.
2010;12:943–950.
17. van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 in
chronic hemodialysis patients is related to residual kidney function and
not to treatment with erythropoiesis stimulating agents. PLoS One.
2012;7:e39783.
18. Kroot JJ, Tjalsma H, Fleming RE, et al. Hepcidin in human iron disorders:
diagnostic implications. Clin Chem. 2011;57:1650–1669.
19. Kroot JJ, van Herwaarden AE, Tjalsma H, et al. Second round robin for
plasma hepcidin methods: ﬁrst steps toward harmonization. Am J
Hematol. 2012;87:977–983.Kidney International (2016) 89, 28–3920. Macdougall IC, Malyszko J, Hider RC, et al. Current status of the
measurement of blood hepcidin levels in chronic kidney disease.
Clin J Am Soc Nephrol. 2010;5:1681–1689.
21. Gualdi R, Casalgrandi G, Montosi G, et al. Excess iron into hepatocytes is
required for activation of collagen type I gene during experimental
siderosis. Gastroenterology. 1994;107:1118–1124.
22. Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis
in adults without pathogenic mutations in the hemochromatosis gene.
N Engl J Med. 1999;341:725–732.
23. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms
of iron-induced hepatic ﬁbrogenesis. Semin Liver Dis. 2005;25:
433–449.
24. Canavese C, Bergamo D, Ciccone G, et al. Validation of serum ferritin
values by magnetic susceptometry in predicting iron overload in
dialysis patients. Kidney Int. 2004;65:1091–1098.
25. Ferrari P, Kulkarni H, Dheda S, et al. Serum iron markers are inadequate
for guiding iron repletion in chronic kidney disease. Clin J Am Soc
Nephrol. 2011;6:77–83.
26. Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron
overload in long-term hemodialysis patients and the impact of
withdrawing parenteral iron. Eur J Haematol. 2012;89:87–93.
27. Arosio P, Yokota M, Drysdale JW. Characterization of serum ferritin in
iron overload: possible identity to natural apoferritin. Br J Haematol.
1977;36:199–207.
28. van Bokhoven MA, van Deursen CT, Swinkels DW. Diagnosis and
management of hereditary haemochromatosis. BMJ. 2011;342:c7251.
29. Hershko C. Pathogenesis and management of iron toxicity in
thalassemia. Ann N Y Acad Sci. 2010;1202:1–9.
30. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of
hepatic iron stores by MRI. Lancet. 2004;363:357–362.
31. St Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement
and imaging of liver iron concentrations using proton magnetic
resonance. Blood. 2005;105:855–861.
32. Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated
hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI
study. Am J Med. 2012;125:991–999.e1.
33. European Association for the Study of the Liver. EASL clinical practice
guidelines for HFE hemochromatosis. J Hepatol. 2010;53:3–22.
34. Bailie GR, Larkina M, Goodkin DA, et al. Variation in intravenous iron use
internationally and over time: the Dialysis Outcomes and Practice
Patterns Study (DOPPS). Nephrol Dial Transplant. 2013;28:2570–2579.
35. Charytan DM, Pai AB, Chan CT, et al. Considerations and challenges in
deﬁning optimal iron utilization in hemodialysis. J Am Soc Nephrol.
2015;26:1238–1247.
36. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia:
oxidant stress as a unifying concept of cardiovascular disease in uremia.
Kidney Int. 2002;62:1524–1538.
37. Massy ZA, Stenvinkel P, Drueke TB. The role of oxidative stress in
chronic kidney disease. Semin Dial. 2009;22:405–408.
38. Tucker PS, Dalbo VJ, Han T, et al. Clinical and research markers of
oxidative stress in chronic kidney disease. Biomarkers. 2013;18:103–115.
39. Kuo KL, Hung SC, Wei YH, et al. Intravenous iron exacerbates oxidative
DNA damage in peripheral blood lymphocytes in chronic hemodialysis
patients. J Am Soc Nephrol. 2008;19:1817–1826.
40. Tovbin D, Mazor D, Vorobiov M, et al. Induction of protein oxidation by
intravenous iron in hemodialysis patients: role of inﬂammation. Am J
Kidney Dis. 2002;40:1005–1012.
41. Pai AB, Boyd AV, McQuade CR, et al. Comparison of oxidative stress
markers after intravenous administration of iron dextran, sodium ferric
gluconate, and iron sucrose in patients undergoing hemodialysis.
Pharmacotherapy. 2007;27:343–350.
42. Martin-Malo A, Merino A, Carracedo J, et al. Effects of intravenous iron
on mononuclear cells during the haemodialysis session. Nephrol Dial
Transplant. 2012;27:2465–2471.
43. Kamanna VS, Ganji SH, Shelkovnikov S, et al. Iron sucrose promotes
endothelial injury and dysfunction and monocyte adhesion/inﬁltration.
Am J Nephrol. 2012;35:114–119.
44. Rooyakkers TM, Stroes ES, Kooistra MP, et al. Ferric saccharate induces
oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin
Invest. 2002;32(suppl 1):9–16.
45. Sullivan JL. Iron in arterial plaque: modiﬁable risk factor for atherosclerosis.
Biochim Biophys Acta. 2009;1790:718–723.
46. Kautz L, Gabayan V, Wang X, et al. Testing the iron hypothesis in a
mouse model of atherosclerosis. Cell Rep. 2013;5:1436–1442.37
meet ing repor t IC Macdougall et al.: Iron management in CKD: a KDIGO executive summary report47. Kuo KL, Hung SC, Lee TS, et al. Iron sucrose accelerates early
atherogenesis by increasing superoxide production and upregulating
adhesion molecules in CKD. J Am Soc Nephrol. 2014;25:2596–2606.
48. Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent
associations between iron and mortality in hemodialysis patients. J Am
Soc Nephrol. 2005;16:3070–3080.
49. Drueke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced
oxidation protein products, and carotid artery intima-media thickness
in end-stage renal disease. Circulation. 2002;106:2212–2217.
50. Reis KA, Guz G, Ozdemir H, et al. Intravenous iron therapy as a possible
risk factor for atherosclerosis in end-stage renal disease. Int Heart J.
2005;46:255–264.
51. Kuo KL, Hung SC, Lin YP, et al. Intravenous ferric chloride hexahydrate
supplementation induced endothelial dysfunction and increased
cardiovascular risk among hemodialysis patients. PLoS One. 2012;7:
e50295.
52. Kshirsagar AV, Freburger JK, Ellis AR, et al. Intravenous iron
supplementation practices and short-term risk of cardiovascular events
in hemodialysis patients. PLoS One. 2013;8:e78930.
53. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med.
2012;366:348–359.
54. Zhang X, Rovin BH. Beyond anemia: hepcidin, monocytes and
inﬂammation. Biol Chem. 2013;394:231–238.
55. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis.
Science. 2012;338:768–772.
56. Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin
in men: a potential mechanism for testosterone-induced erythrocytosis.
J Clin Endocrinol Metab. 2010;95:4743–4747.
57. Yang Q, Jian J, Katz S, et al. 17b-Estradiol inhibits iron hormone
hepcidin through an estrogen responsive element half-site.
Endocrinology. 2012;153:3170–3178.
58. Kautz L, Jung G, Valore EV, et al. Identiﬁcation of erythroferrone as an
erythroid regulator of iron metabolism. Nat Genet. 2014;46:678–684.
59. Valenti L, Dongiovanni P, Motta BM, et al. Serum hepcidin and
macrophage iron correlate with MCP-1 release and vascular damage in
patients with metabolic syndrome alterations. Arterioscler Thromb Vasc
Biol. 2011;31:683–690.
60. Galesloot TE, Holewijn S, Kiemeney LA, et al. Serum hepcidin is
associated with presence of plaque in postmenopausal women of a
general population. Arterioscler Thromb Vasc Biol. 2014;34:446–456.
61. Saeed O, Otsuka F, Polavarapu R, et al. Pharmacological suppression of
hepcidin increases macrophage cholesterol efﬂux and reduces foam
cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol.
2012;32:299–307.
62. Kuragano T, Itoh K, Shimonaka Y, et al. Hepcidin as well as TNF-alpha
are signiﬁcant predictors of arterial stiffness in patients on maintenance
hemodialysis. Nephrol Dial Transplant. 2011;26:2663–2667.
63. van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 is related
to cardiovascular events in chronic haemodialysis patients. Nephrol Dial
Transplant. 2013;28:3062–3071.
64. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis
patients. Nephrol Dial Transplant. 2014;29:255–259.
65. Salonen JT, Nyyssonen K, Korpela H, et al. High stored iron levels are
associated with excess risk of myocardial infarction in eastern Finnish
men. Circulation. 1992;86:803–811.
66. Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are
associated with vascular damage in patients with nonalcoholic fatty
liver disease. Nutr Metab Cardiovasc Dis. 2011;21:568–575.
67. Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. A low serum iron level is
a predictor of poor outcome in hemodialysis patients. Am J Kidney Dis.
2004;43:671–684.
68. Roob JM, Khoschsorur G, Tiran A, et al. Vitamin E attenuates oxidative
stress induced by intravenous iron in patients on hemodialysis. J Am
Soc Nephrol. 2000;11:539–549.
69. Swarnalatha G, Ram R, Neela P, et al. Oxidative stress in hemodialysis
patients receiving intravenous iron therapy and the role of N-
acetylcysteine in preventing oxidative stress. Saudi J Kidney Dis Transpl.
2010;21:852–858.
70. Conner TA, McQuade C, Olp J, et al. Effect of intravenous vitamin C on
cytokine activation and oxidative stress in end-stage renal disease
patients receiving intravenous iron sucrose. Biometals. 2012;25:961–969.
71. Himmelfarb J, Ikizler TA, Ellis C, et al. Provision of antioxidant therapy in
hemodialysis (PATH): a randomized clinical trial. J Am Soc Nephrol.
2014;25:623–633.3872. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J.
2011;434:365–381.
73. Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of
mammalian iron metabolism. Cell. 2010;142:24–38.
74. Weinberg ED. Iron availability and infection. Biochim Biophys Acta.
2009;1790:600–605.
75. Nairz M, Schroll A, Sonnweber T, et al. The struggle for iron—a metal at
the host–pathogen interface. Cell Microbiol. 2010;12:1691–1702.
76. Weiss G, Schett G. Anaemia in inﬂammatory rheumatic diseases.
Nat Rev Rheumatol. 2013;9:205–215.
77. Ganz T. Iron in innate immunity: starve the invaders. Curr Opin Immunol.
2009;21:63–67.
78. Ishida JH, Johansen KL. Iron and infection in hemodialysis patients.
Semin Dial. 2014;27:26–36.
79. Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy
with intravenous iron therapy in hemodialysis patients. J Am Soc
Nephrol. 2000;11:530–538.
80. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly
efﬁcacious in anemic hemodialysis patients with high serum ferritin
and low transferrin saturation: results of the Dialysis Patients’ Response
to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol.
2007;18:975–984.
81. Kapoian T, O’Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin
requirements in hemodialysis patients with elevated ferritin. J Am Soc
Nephrol. 2008;19:372–379.
82. Sirken G, Raja R, Rizkala AR. Association of different intravenous iron
preparations with risk of bacteremia in maintenance hemodialysis
patients. Clin Nephrol. 2006;66:348–356.
83. Diskin CJ, Stokes TJ, Dansby LM, et al. Is systemic heparin a risk factor
for catheter-related sepsis in dialysis patients? An evaluation of
various bioﬁlm and traditional risk factors. Nephron Clin Pract.
2007;107:c128–c132.
84. Brookhart MA, Freburger JK, Ellis AR, et al. Infection risk with bolus
versus maintenance iron supplementation in hemodialysis patients.
J Am Soc Nephrol. 2013;24:1151–1158.
85. Kuragano T, Matsumura O, Matsuda A, et al. Association between
hemoglobin variability, serum ferritin levels, and adverse events/mortality
in maintenance hemodialysis patients. Kidney Int. 2014;86:845–854.
86. Bailie GR, Larkina M, Goodkin DA, et al. Data from the Dialysis
Outcomes and Practice Patterns Study validate an association between
high intravenous iron doses and mortality. Kidney Int. 2015;87:162–168.
87. Tangri N, Miskulin DC, Zhou J, et al. Effect of intravenous iron use on
hospitalizations in patients undergoing hemodialysis: a comparative
effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial
Transplant. 2015;30:667–675.
88. Zitt E, Sturm G, Kronenberg F, et al. Iron supplementation and mortality
in incident dialysis patients: an observational study. PLoS One. 2014;
9:e114144.
89. Susantitaphong P, Alqahtani F, Jaber BL. Efﬁcacy and safety of
intravenous iron therapy for functional iron deﬁciency anemia in
hemodialysis patients: a meta-analysis. Am J Nephrol. 2014;39:130–141.
90. Litton E, Xiao J, Ho KM. Safety and efﬁcacy of intravenous iron therapy
in reducing requirement for allogeneic blood transfusion: systematic
review and meta-analysis of randomised clinical trials. BMJ. 2013;
347:f4822.
91. Muñoz M, Auerbach M, Shander A. Re: Safety and efﬁcacy of
intravenous iron therapy in reducing requirement for allogeneic blood
transfusion: systematic review and meta-analysis of randomised clinical
trials. BMJ. 13 September 2013. Available at: http://www.bmj.com/
content/347/bmj.f4822/rr/661826. Accessed 17 September 2015.
92. Prakash S, Walele A, Dimkovic N, et al. Experience with a large dose
(500 mg) of intravenous iron dextran and iron saccharate in peritoneal
dialysis patients. Perit Dial Int. 2001;21:290–295.
93. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and
oral iron in chronic kidney disease. Kidney Int. 2015;88:905–914.
94. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of
intravenous ferric carboxymaltose versus oral iron in patients with
chronic kidney disease and iron deﬁciency anaemia. Nephrol Dial
Transplant. 2014;29:2075–2084.
95. Chaplin S, Bhandari S. Oral iron: properties and current place in the
treatment of anaemia. Prescriber. 2012;23:12–18.
96. de Barrio M, Fuentes V, Tornero P, et al. Anaphylaxis to oral iron salts.
Desensitization protocol for tolerance induction. J Investig Allergol Clin
Immunol. 2008;18:305–308.Kidney International (2016) 89, 28–39
IC Macdougall et al.: Iron management in CKD: a KDIGO executive summary report mee t ing repor t97. Heath CW, Strauss MB, Castle WB. Quantitative aspects of iron
deﬁciency in hypochromic anemia: the parenteral administration of
iron. J Clin Invest. 1932;11:1293–1312.
98. Auerbach M, Strauss W, Auerbach S, et al. Safety and efﬁcacy of total
dose infusion of 1,020 mg of ferumoxytol administered over 15 min.
Am J Hematol. 2013;88:944–947.
99. Macdougall IC. Iron supplementation in the non-dialysis chronic kidney
disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin.
2010;26:473–482.
100. Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in
patients with iron-deﬁciency anemia and impaired renal function: the
REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29:833–842.
101. Wikstrom B, Bhandari S, Barany P, et al. Iron isomaltoside 1000: a new
intravenous iron for treating iron deﬁciency in chronic kidney disease.
J Nephrol. 2011;24:589–596.
102. Moniem KA, Bhandari S. Tolerability and efﬁcacy of parenteral iron
therapy in hemodialysis patients. Trans Alt Trans Med. 2007;9:37–42.
103. FDA strengthens warnings and changes prescribing instructions to
decrease the risk of serious allergic reactions with anemia drug
Feraheme (ferumoxytol). US Food and Drug Administration, Drug
Safety Communications. Available at: http://www.fda.gov/downloads/
Drugs/DrugSafety/UCM440336.pdf. Accessed 18 May 2015.
104. Fishbane SN, Singh AK, Cournoyer SH, et al. Ferric pyrophosphate
citrate (Triferic) administration via the dialysate maintains hemoglobin
and iron balance in chronic hemodialysis patients [e-pub ahead of
print] Nephrol Dial Transplant. 13 July 2015. http://dx.doi.org/10.1093/
ndt/gfv277.
105. Yokoyama K, Hirakata H, Akiba T, et al. Ferric citrate hydrate for the
treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J
Am Soc Nephrol. 2014;9:543–552.
106. Barraclough KA, Brown F, Hawley CM, et al. A randomized controlled
trial of oral heme iron polypeptide versus oral iron supplementation for
the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT
trial. Nephrol Dial Transplant. 2012;27:4146–4153.
107. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for
anaemia. Lancet. 2007;369:1502–1504.
108. Charytan C, Schwenk MH, Al-Saloum MM, et al. Safety of iron sucrose in
hemodialysis patients intolerant to other parenteral iron products.
Nephron Clin Pract. 2004;96:c63–c66.
109. EU Clinical Trials Register. Available at: https://www.clinicaltrialsregister.
eu/ctr-search/trial/2013-002267-25/GB. Accessed 18 May 2015.
110. Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for
evaluating cardiovascular risk in the chronic kidney disease patient:
how do new pieces ﬁt into the uremic puzzle? Clin J Am Soc Nephrol.
2008;3:505–521.
111. Li JJ, Meng X, Si HP, et al. Hepcidin destabilizes atherosclerotic plaque
via overactivating macrophages after erythrophagocytosis. Arterioscler
Thromb Vasc Biol. 2012;32:1158–1166.
112. Ring J, Grosber M, Mohrenschlager M, et al. Anaphylaxis: acute
treatment and management. Chem Immunol Allergy. 2010;95:201–210.
113. Eschbach JW, Cook JD, Finch CA. Iron absorption in chronic renal
disease. Clin Sci. 1970;38:191–196.
114. Kooistra MP, Marx JJ. The absorption of iron is disturbed in recombinant
human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial
Transplant. 1998;13:2578–2582.
115. Kooistra MP, Niemantsverdriet EC, van Es A, et al. Iron absorption in
erythropoietin-treated haemodialysis patients: effects of iron
availability, inﬂammation and aluminium. Nephrol Dial Transplant.
1998;13:82–88.
116. Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of
intravenous iron dextran in hemodialysis patients. Am J Kidney Dis.
1996;28:529–534.
117. Esposito BP, Breuer W, Slotki I, et al. Labile iron in parenteral iron
formulations and its potential for generating plasma nontransferrin-
bound iron in dialysis patients. Eur J Clin Invest. 2002;32(suppl 1):42–49.Kidney International (2016) 89, 28–39118. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron
formulations: a quantitative and comparative study. Nephrol Dial
Transplant. 2004;19:561–565.
119. Atalay H, Solak Y, Acar K, et al. Safety proﬁles of total dose infusion of
low-molecular-weight iron dextran and high-dose iron sucrose in renal
patients. Hemodial Int. 2011;15:374–378.
120. Barton JC, Barton EH, Bertoli LF, et al. Intravenous iron dextran therapy
in patients with iron deﬁciency and normal renal function who failed to
respond to or did not tolerate oral iron supplementation. Am J Med.
2000;109:27–32.
121. European Medicines Agency. Procedure no. EMEA/H/A-31/1322,
September 2013.
122. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in
patients with heart failure and iron deﬁciency. N Engl J Med. 2009;361:
2436–2448.
123. Viethen T, Gerhardt F, Dumitrescu D, et al. Ferric carboxymaltose
improves exercise capacity and quality of life in patients with
pulmonary arterial hypertension and iron deﬁciency: a pilot study.
Int J Cardiol. 2014;175:233–239.
124. Trotti LM, Bhadriraju S, Becker LA. Iron for restless legs syndrome.
Cochrane Database Syst Rev. 2012;5:CD007834.
125. Mehmood T, Auerbach M, Earley CJ, et al. Response to intravenous iron
in patients with iron deﬁciency anemia (IDA) and restless leg syndrome
(Willis-Ekbom disease). Sleep Med. 2014;15:1473–1476.
126. Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric
carboxymaltose in fatigued, iron-deﬁcient women—PREFER a
randomized, placebo-controlled study. PLoS One. 2014;9:e94217.
127. Krayenbuehl PA, Battegay E, Breymann C, et al. Intravenous iron for the
treatment of fatigue in nonanemic, premenopausal women with low
serum ferritin concentration. Blood. 2011;118:3222–3227.
128. Niihata K, Tomosugi N, Uehata T, et al. Serum hepcidin-25 levels predict
the progression of renal anemia in patients with non-dialysis chronic
kidney disease. Nephrol Dial Transplant. 2012;27:4378–4385.
129. Pai AB, Conner T, McQuade CR, et al. Non-transferrin bound iron,
cytokine activation and intracellular reactive oxygen species generation
in hemodialysis patients receiving intravenous iron dextran or iron
sucrose. Biometals. 2011;24:603–613.
130. Danielson BG. Structure, chemistry, and pharmacokinetics of
intravenous iron agents. J Am Soc Nephrol. 2004;15(suppl 2):S93–S98.
131. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to
colloid volume substitutes. Lancet. 1977;1:466–469.APPENDIX
Other Conference Participants
John W. Adamson, USA; Tadao Akizawa, Japan; Stefan D. Anker,
Germany; Michael Auerbach, USA; Peter Bárány, Sweden; Anatole
Besarab, USA; Sunil Bhandari, UK; Ioav Cabantchik, Israel; Alan
J. Collins, USA; Daniel W. Coyne, USA; Ángel L.M. de Francisco, Spain;
Steven Fishbane, USA; Carlo A.J.M. Gaillard, the Netherlands;
Tomas Ganz, USA; David J. Goldsmith, UK; Chaim Hershko, Israel;
Ewa A. Jankowska, Poland; Kirsten L. Johansen, USA; Kamyar
Kalantar-Zadeh, USA; Philip A. Kalra, UK; Bertram L. Kasiske, USA;
Francesco Locatelli, Italy; Jolanta Małyszko, Poland; Gert Mayer,
Austria; Lawrence P. McMahon, Australia; Ashraf Mikhail, UK;
Elizabeta Nemeth, USA; Amy Barton Pai, USA; Patrick S. Parfrey,
Canada; Roberto Pecoits-Filho, Brazil; Simon D. Roger, Australia;
Guy Rostoker, France; Jacques Rottembourg, France; Ajay K. Singh,
USA; Itzchak Slotki, Israel; Bruce S. Spinowitz, USA; Der-Cherng Tarng,
Taiwan; Francesca Tentori, USA; Jorge E. Toblli, Argentina; Yusuke
Tsukamoto, Japan; Nosratola D. Vaziri, USA; Wolfgang C. Winkelmayer,
USA; David C. Wheeler, UK; Elena Zakharova, Russia39
